Document:

<PAGE>

                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED

                                                                    Exhibit 10.9

                 FOURTH AMENDMENT TO COLLABORATIVE RESEARCH AND
                DEVELOPMENT AGREEMENT DATED 1ST SEPTEMBER, 1995

This Amendment ("Amendment") dated February 27, 2001, is entered into by and
between:

E. I. du Pont de Nemours and Company, a corporation organized under the laws of
the State of Delaware and having its principal place of business at 1007 Market
Street, Wilmington, DE 19898 ("DuPont")

And

Genencor International, Inc., a corporation organized under the laws of the
State of Delaware and having its principal place of business at 925 Page Mill
Road, Palo Alto, CA 94304 ("Genencor")

Whereas:

A.       DuPont and Genencor entered into a Collaborative Research and
         Development Agreement dated 1st September, 1995 ("the Agreement");

B.       DuPont and Genencor have amended the Agreement pursuant to letter
         agreements dated 23rd July, 1997 (the "First Letter Amendment"), 31st
         March, 1998 (the "Second Letter Amendment"), and 19th February, 1999
         (the "Third Letter Amendment") together referred to hereafter as the
         "Letter Agreements"; and

C.       DuPont and Genencor wish further to amend the Agreement as set out
         herein.

NOW THEREFORE, DuPont and Genencor enter into this Fourth Amendment and agree as
follows:

1.       Unless otherwise indicated to the contrary all capitalized terms shall
         bear the meaning assigned to them in the Agreement as amended by the
         Letter Agreements.

2.       The provision of the Agreement relating to the GEN III technical
         milestone (Section 3.3 as amended by the Second Letter Amendment) shall
         remain in full force and effect through [...***...]. If the Steering
         Committee determines that no organism meeting the GEN III technical
         milestones has been developed by that date, there will be no payment
         for the GEN III Milestone.

3.       The term of the Agreement shall be extended and the Agreement shall
         terminate (unless terminated sooner as provided in the Agreement) on
         31st December, 2001 (the earliest of any such dates being referred to
         as the "Termination Date").

<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

4.       The provisions of the Agreement relating to the pre-commercial
         milestone (Section 4.1 as amended), shall be amended to read:

         4.1 "PRE-COMMERCIAL MILESTONE. DuPont will pay Genencor a
         non-refundable, lump sum payment of [...***...] upon the cumulative
         Bioprocess production of [...***...] of Compound X made under a Tier I
         or II exemption, as defined by Toxic Substances Control Act, relating
         to the use of intergeneric recombinant microorganisms during the
         Pre-Commercial Phase, regardless of whether the so-produced Compound X
         are made by DuPont, or for DuPont by a toll manufacturer, or by
         Genencor.

5.       Article 4 of the Agreement shall be amended by adding the following
         Paragraph 4.2A

         4.2A
                  (i)      In the event that the Bioprocess is commercialized to
                           the extent that it is operating under a Tier I or II
                           exemption, as defined by Toxic Substances Control
                           Act, relating to the use of intergeneric recombinant
                           microorganisms, based on an organism developed during
                           the term of this Agreement (as extended) but the
                           CCOM, measured in accordance with Sections 4.3 and
                           4.4, is greater than [...***...], and the technical
                           milestones set out in Table IIIB are accomplished,
                           DuPont shall pay to Genencor the relevant milestone
                           payment set out in Table IIIB. The relevant technical
                           milestones shall be deemed to have been accomplished
                           when all [...***...] parameters have been achieved at
                           a scale of [...***...]or larger in at least
                           [...***...] batches. At its discretion the Steering
                           Committee may deem [...***...] consecutive successful
                           batches as meeting the relevant milestone.

                  (ii)   In the event that CCOM, measured in accordance with
                         Sections 4.3 and 4.4, is [...***...] or less, the
                         provisions of Section 4.2 shall apply and any milestone
                         payment shall be based upon Table IIIA.

6.       Section 4.4 of the Agreement shall be amended to read:

         4.4      CCOM CALCULATION. The amount of the bonus Commercial Milestone
                  payment and applicable Royalty rate are determined by the
                  [...***...] calculation of the CCOM of Compound X in a
                  commercial scale manufacturing plant in accordance with
                  Article IV and Table IIIA herein and the following equation
                  for calculating CCOM:

                  CCOM = [...***...]

                  [...***...]

                  [...***...]

                  [...***...]

                  [...***...]

                                      -2-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

                  (e)    Each By-Product has an economic value depending on
                         whether it is sold, recycled, or disposed of upon
                         removal from Bioprocess. The actual costs and credit
                         for the disposition of By-Products shall be calculated
                         for use in determining CCOM of Compound X;

                  (f)    The CCOM arrived at under the operation of Section 4.4
                         is solely for the purpose of determining a [...***...]
                         Commercial Milestone payment and Commercial Royalties
                         due to Genencor (subject to adjustment pursuant to
                         Section 6.5 as amended). Choice of actual manufacturing
                         processes and disposition methods of By-Products are
                         solely the responsibility of DuPont.

7.       Table III shall be replaced by the following:

                                   TABLE IIIA

   CCOM IN COMMERCIAL SCALE MFG. PLANT              BONUS MILESTONE PAYMENT
   -----------------------------------              -----------------------
               [...***...]                                 [...***...]

  For CCOMs in between the stated rates, the bonus milestone payment to Genencor
  will be interpolated

                                   TABLE IIIB

       [...***...]

8.       Section 6.5 of the Agreement shall be amended to read:

         ROYALTY PAYMENT: Subject to the end of year adjustment as provided
         below, Commercial Royalties shall be calculated based upon the original
         CCOM determined in accordance with Article IV hereof, as adjusted
         annually based upon [...***...] for the current royalty year and shall
         be paid monthly within sixty (60) days after the last day of each
         month, for a period of [...***...] from the beginning of the Commercial
         Phase or [...***...] from the Effective Date of the Agreement,
         whichever period is [...***...]. At the end of each year when the
         [...***...] for the relevant year is known, the parties shall
         recalculate the CCOM for such year based on the [...***...] compared to
         the [...***...] for the relevant year and from such recalculated CCOM
         the parties shall determine the final sum for the Commercial Royalty
         due to Genencor for the relevant year. In the event that the final sum
         for the Commercial Royalty is less than the payments made during the
         relevant royalty year, DuPont shall pay to Genencor the amount of such
         shortfall with the first royalty payment of the following year. In the
         event that the final sum for the Commercial Royalty exceeds the
         payments made during the relevant royalty year, such excess shall be
         credited against the first royalty payment due from DuPont to Genencor
         in the following year.

9.       R&D EXPENSES: Notwithstanding the provisions of Section 2.3 of the
         Agreement (as amended pursuant to the Third Letter Agreement), DuPont
         and Genencor agree that as of

                                      -3-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

         1st March, 2001 and for the remaining term of the Agreement as extended
         by this Fourth Amendment, DuPont shall pay Genencor for R&D expenses
         for work on the R&D Program at the rate of [...***...] per each of the
         full time Scientific Personnel assigned to the R&D Program. The rate
         set for Scientific Personnel includes the cost of Support Personnel and
         overhead. It is anticipated that the level of staffing prior to the
         effective date of the extension shall be [...***...] full time
         Scientific Personnel. Furthermore it is anticipated that the level of
         staffing during the first three months of the extension (March 1, 2001
         - May 31, 2001) shall be between [...***...] full time Scientific
         Personnel, although the actual number shall remain under the direction
         and adjustment of the Steering Committee.

10.      In the event that DuPont forms a [...***...] with [...***...] or any of
         its subsidiaries or affiliates for commercialization of Compound X, the
         parties agree to encourage the [...***...] and Genencor to enter into
         discussions with regard to the possibility of Genencor entering into an
         agreement with such [...***...] for further development of the
         Bioprocess efficiency.

11.      Section 1.9 of the Agreement (as amended pursuant to the Third Letter
         Amendment) shall be further amended to read:

         "Compound X" shall mean [...***...] and 1,3-propanediol and derivatives
         of 1,3 propanediol. For the purposes of calculating the R&D-Based
         Milestones under Article 3, CCOM and Pre-commercial and commercial
         Milestone payments of Article 4, the Royalty Payments to GENENCOR under
         Article 6, and for calculations under 10.6-10.7 of Article 10,
         "Compound X" shall mean [...***...].

12.      The first sentence of Section 2.1 of the Agreement shall be amended to
         read:

         Each Party will appoint two of its employees to serve on the Steering
         Committee.

13.      The first sentence of Section 1.8 of the Agreement shall be amended to
         read:

         DuPont will determine Commercial Specification for Compound X after
         review and comment by Genencor.

14.      Section 1.19 shall be amended to read:

         "Pre-Commercial Phase" shall mean the period starting with the first
         Bioprocess production of Compound X operated under a Tier I or II
         exemption, as defined by Toxic Substances Control Act, relating to the
         use of intergeneric recombinant microorganisms up to the cumulative
         Bioprocess production of [...***...] of Compound X made under said
         exemption.

15.      Consistent with the Third Letter Amendment the parties hereby agree
         that [...***...] Genencor, shall remain a consultant to DuPont for the
         purpose of enhancing the successful commercialization of 1,3
         propanediol produced by the Bioprocess. The parties will execute a
         separate confidentiality agreement as necessary to implement such
         consultancy.

                                      -4-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

16.      All other provisions of the Agreement, as amended by the Letter
         Agreements, not specifically amended as set out herein, shall remain in
         full force and effect.

[REST OF PAGE INTENTIONALLY LEFT BLANK]

                                      -5-
<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED

IN WITNESS WHEREOF, the Parties hereto have executed this Amendment

GENENCOR INTERNATIONAL, INC.                 E.I. DU PONT DE NEMOURS AND COMPANY

BY:  /s/  Thomas J. Pekich                   By:  /s/ (signature illegible)
     ------------------------------------         ------------------------------
        Thomas J. Pekich
TITLE:  Group Vice President                          TITLE: Business Director
        Industrial Chemicals                                 Bio-Based Materials
DATE:   Feb. 27, 2001                                 DATE:  2/27/01<PAGE>
                                            ***TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED

                                                                   Exhibit 10.10

                  FIFTH AMENDMENT TO COLLABORATIVE RESEARCH AND
                 DEVELOPMENT AGREEMENT DATED 1ST SEPTEMBER, 1995

This Amendment (the "Fifth Amendment") dated 1 December 2001, is entered into by
and between:

E. I. du Pont de Nemours and Company, a corporation organized under the laws of
the State of Delaware and having its principal place of business at 1007 Market
Street, Wilmington, DE 19898 ("DuPont")

and

Genencor International, Inc., a corporation organized under the laws of the
State of Delaware and having its principal place of business at 925 Page Mill
Road, Palo Alto, CA 94304 ("Genencor").

Whereas:

A.       DuPont and Genencor entered into a Collaborative Research and
         Development Agreement dated 1st September, 1995 ("the Agreement");

B.       DuPont and Genencor have amended the Agreement pursuant to letter
         agreements dated 23rd July 1997 (the "First Letter Amendment"), 31st
         March 1998 (the "Second Letter Amendment"), 19th February 1999 (the
         "Third Letter Amendment"), and 27 February 2001 (the "Fourth Letter
         Amendment) (collectively referred to as "the Letter Amendments").

C.       DuPont and Genencor wish further to amend the Agreement as set out
         herein.

         NOW THEREFORE, DuPont and Genencor enter into this Fifth Letter
         Amendment and agree as follows:

1.       Unless otherwise indicated, all capitalized terms shall bear the
         meaning assigned to them in the Agreement;

2.       The term of the Agreement shall be extended and the Agreement shall
         terminate (unless terminated sooner as provided in the Agreement) on 30
         June 2002 (the earliest of any such dates being referred to as "the
         Termination Date");

3.       ROYALTY PAYMENT: Notwithstanding the provisions of Section 6.5 of the
         Agreement (as amended by the Fourth Letter Agreement), DuPont and
         Genencor agree that, as of 1 January 2002 and for the remaining term of
         this Agreement as extended by this Fifth Letter Amendment and subject
         to the end-of-the-year adjustment as provided below, Commercial
         Royalties shall be calculated based upon the original CCOM determined
         in accordance with Article IV of the Agreement (as amended by the
         Fourth Letter Agreement), as

<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED
                                                                               2

Fifth Amendment to
Collaborative R&D Agreement of 1 September 1955

         adjusted annually based upon [...***...] for the current royalty year.
         This royalty shall be paid monthly within sixty (60) days after the
         last day of each month, for a period of [...***...] from the beginning
         of the Commercial Phase. At the end of each year when the [...***...]
         for the relevant year is known, the parties shall recalculate the CCOM
         for such year based on the [...***...] compared to the [...***...] for
         the relevant year and from such recalculated CCOM the parties shall
         determine the final sum for the Commercial Royalty due to Genencor for
         the relevant year. In the event that the final sum for the Commercial
         Royalty is less than the payments made during the relevant royalty
         year, DuPont shall pay to Genencor the amount of such shortfall with
         the first royalty payment of the following year. In the event that the
         final sum for the Commercial Royalty exceeds the payments made during
         the relevant royalty year, such excess shall be credited against the
         first royalty payment due from DuPont to Genencor in the following
         year.

4.       R&D EXPENSES: Notwithstanding the provisions of Section 2.3 of the
         Agreement (as amended pursuant to the Third and Fourth Letter
         Amendments), DuPont and Genencor agree that as of 1st January, 2002 and
         for the remaining term of the Agreement as extended by this Fifth
         Letter Amendment, DuPont shall pay Genencor for R&D expenses for work
         on the R&D Program at the rate of [...***...] per each of the full time
         Scientific Personnel assigned to the R&D Program. The rate set for
         Scientific Personnel includes the cost of Support Personnel and
         overhead. It is anticipated that the level of staffing prior to the
         effective date of the extension shall be between [...***...] full time
         Scientific Personnel. Furthermore, it is anticipated that the level of
         staffing after the effective date of the extension (1 January 2002)
         shall be [...***...] full time Scientific Personnel, although the
         actual number shall remain under the direction and adjustment of the
         Steering Committee.

5.       Consistent with the Fourth Letter Agreement, the provision of the
         Agreement relating to the GEN III technical milestone (Section 3.3 as
         amended by the Second Letter Amendment) shall remain in full force and
         effect [...***...]. If the Steering Committee determines that no
         organism meeting the GEN III technical milestone has been developed by
         that date, there will be no payment for the GEN III Milestone.

6.       Consistent with the Third and Fourth Letter Agreements, the Parties
         hereby agree that [...***...], Genencor, shall remain a consultant to
         DuPont for the purpose of enhancing the successful commercialization of
         1,3-propanediol produced by the Bioprocess. The Parties will execute a
         separate agreement as necessary to implement such consultancy.

7.       All other provisions of the Agreement, as amended by the previous
         Letter Agreements, and not specifically amended as set out herein,
         shall remain in full force and effect.

<PAGE>

                                               *CONFIDENTIAL TREATMENT REQUESTED
                                                                               3

Fifth Amendment to
Collaborative R&D Agreement of 1 September 1955

         In keeping with subparagraph 11.7 of the Collaborative Research and
Development Agreement, please indicate acceptance of the foregoing amendments
and terms by obtaining the signature of an authorized officer of Genencor.

IN WITNESS WHEREOF, the Parties hereto have executed this Fifth Amendment.

GENENCOR INTERNATIONAL, INC.            E.I. DU PONT DE NEMOURS AND COMPANY

BY:  /s/  Karl Sanford                  By:  /s/  Ellen J. Kullman
     --------------------------------        ---------------------

NAME:  Karl Sanford                     NAME:  Ellen J. Kullman

TITLE:   VP Tech Dev                    TITLE:   Group VP & GM

DATE:    01/07/02                       DATE:    01/14/02

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]